BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 36722402)

  • 1. The clinical impact of the molecular landscape of acute myeloid leukemia.
    Kayser S; Levis MJ
    Haematologica; 2023 Feb; 108(2):308-320. PubMed ID: 36722402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of molecular markers in acute myeloid leukemia.
    Kayser S; Levis MJ
    Eur J Haematol; 2019 Jan; 102(1):20-35. PubMed ID: 30203623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates on targeted therapies for acute myeloid leukaemia.
    Kayser S; Levis MJ
    Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia transformed to a targetable disease.
    Saleh K; Khalifeh-Saleh N; Kourie HR
    Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
    Stone RM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Treatment Options for Acute Myeloid Leukemia in 2019.
    Cerrano M; Itzykson R
    Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.
    Venugopal S; Xie Z; Zeidan AM
    Expert Rev Hematol; 2023 Feb; 16(2):109-119. PubMed ID: 36718500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
    Fiorentini A; Capelli D; Saraceni F; Menotti D; Poloni A; Olivieri A
    Oncol Ther; 2020 Jun; 8(1):13-32. PubMed ID: 32700072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating newer agents in the treatment of acute myeloid leukemia.
    Raj RV; Abedin SM; Atallah E
    Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will new agents impact survival in AML?
    Rowe JM
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel Strategies to Treat Acute Myeloid Leukemia].
    Gediga MHE; Middeke JM; Ruhnke L
    Dtsch Med Wochenschr; 2023 Apr; 148(8):451-458. PubMed ID: 36990117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute myeloid leukemia].
    Döhner K; Paschka P; Döhner H
    Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and predictions: AML in 2018.
    Rowe JM
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates on the Management of Acute Myeloid Leukemia.
    Huerga-Domínguez S; Villar S; Prósper F; Alfonso-Piérola A
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.
    Kantarjian H; Short NJ; DiNardo C; Stein EM; Daver N; Perl AE; Wang ES; Wei A; Tallman M
    Lancet Haematol; 2021 Dec; 8(12):e922-e933. PubMed ID: 34687602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.